Resverlogix Corp. logo

Resverlogix Corp.

TSX:RVX.TO

Overview | Financials
Company Name Resverlogix Corp.
Symbol RVX.TO
Currency CAD
Price 0.065
Market Cap 18,070,000
Dividend Yield 0%
52-week-range 0.04 - 0.1
Industry Biotechnology
Sector Healthcare
CEO Mr. Donald J. McCaffrey
Website https://www.resverlogix.com

An error occurred while fetching data.

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease,

Related Stocks

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA.TO

0.36 CAD

Spectral Medical Inc. logo

Spectral Medical Inc.

EDT.TO

0.6 CAD

Microbix Biosystems Inc. logo

Microbix Biosystems Inc.

MBX.TO

0.315 CAD

Titan Medical Inc. logo

Titan Medical Inc.

TMD.TO

1.125 CAD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONC.TO

2.12 CAD

Charlotte's Web Holdings, Inc. logo

Charlotte's Web Holdings, Inc.

CWEB.TO

0.335 CAD

Cipher Pharmaceuticals Inc. logo

Cipher Pharmaceuticals Inc.

CPH.TO

15.55 CAD

Avant Brands Inc. logo

Avant Brands Inc.

AVNT.TO

0.155 CAD

Financials

Numbers are in millions USD

Numbers are in millions USD